BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS
    1.
    发明申请
    BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS 审中-公开
    作为GABA受体调节剂的苯二氮卓衍生物

    公开(公告)号:WO0240487A3

    公开(公告)日:2002-09-26

    申请号:PCT/EP0112887

    申请日:2001-11-08

    CPC classification number: C07D487/14

    Abstract: The present invention relates to compounds of formula (I), wherein R is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, trifluoromethyl, trifluoromethoxy or lower alkylthio; R is -C(O)O-lower alkyl, isoxazol, 1,2,4-oxadiazol-3-yl or 1,2,4-oxadiazol-5-yl, which rings may be substituted by lower alkyl, trifluoromethyl or cycloalkyl; R is hydrogen, lower alkyl, -(CH2)n-cycloalkyl, -(CH2)n-halogen, -(CH2)n-pyridin-4-yl, or -(CH2)n-phenyl, wherein the phenyl ring may be substituted by one or two substituents selected from the group consisting of lower alkoxy, halogen, -SO2CH3, phenyl, OCF3, nitro, CF3, -NR2, or is -(CH2)n-indolyl, optionally substituted by lower alkyl or lower alkoxy, or is pyrrolidinyl-5-oxo, -C(O)-NR2, -(CH2)n-OH, -(CH2)n-NR2 or -(CH2)n-benzo[1,3]dioxole; R is hydrogen or lower alkyl; and n is 0, 1, 2 or 3; and to their pharmaceutically acceptable acid addition salts. These compounds have a good affinity to the GABA A alpha 5 receptor and they are therefore useful for the treatment of diseases, related to this receptor.

    Abstract translation: 本发明涉及式(I)化合物,其中R 1是氢,卤素,低级烷基,低级烷氧基,羟基,氰基,三氟甲基,三氟甲氧基或低级烷硫基; R 2是-C(O)O-低级烷基,异恶唑,1,2,4-恶二唑-3-基或1,2,4-恶二唑-5-基,该环可以被低级烷基取代, 三氟甲基或环烷基; (CH 2)n - 卤素, - (CH 2)n - 吡啶-4-基或 - (CH 2)n - 苯基,其中苯基 环可以被一个或两个选自低级烷氧基,卤素,-SO 2 CH 3,苯基,OCF 3,硝基,CF 3,-NR 2或是 - (CH 2)n - 吲哚基的取代基取代,任选被低级烷基或 低级烷氧基或吡咯烷基-5-氧代-C(O)-NR2, - (CH2)n-OH, - (CH2)n-NR2或 - (CH2)n-苯并[1,3] R是氢或低级烷基; 并且n为0,1,2或3; 及其药学上可接受的酸加成盐。 这些化合物对GABA Aα5受体具有良好的亲和力,因此它们可用于治疗与该受体有关的疾病。

    TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS

    公开(公告)号:CA2590333C

    公开(公告)日:2013-01-08

    申请号:CA2590333

    申请日:2005-12-05

    Abstract: The present invention is concerned with substituted imidazo [1,5-a] [1,2,4] triazolo [1,5-d] [1,4]benzodiazepine derivatives of the following formula (I) wherein R' is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, nitro, cycloalkyl, -O(CH2)mO(CH2)mOH or -C.ident.C-R'; R2 is hydrogen or methyl; R3 is lower alkyl, lower alkyl substituted by halogen, lower alkenyl, lower alkenyl substituted by halogen, lower alkynyl, -(CH2)n-cycloalkyl, -(CR'R")m CH3, or is phenyl, unsubstituted or substituted by halogen, or is pyridinyl or thienyl, unsubstituted or substituted by lower alkyl, or is -(CH2)n-NH-cycloalkyl, lower alkenyl-cycloalkyl, lower alkynyl-(CR'R")mOH, or is lower alkynyl-phenyl, wherein the phenyl ring is unsubstituited or substituted by halogen, CF3, lower alkyl or lower alkoxy; R' is hydrogen or lower alkyl; R" is hydrogen, hydroxy or lower alkyl; n is 0, 1 or 2; m is 1, 2 or 3; o is 1 or 2; and with their pharmaceutically acceptable acid addition salts. It has been found that this class of compounds show high affinity and selectivity for GABA A .alpha. 5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.

    6.
    发明专利
    未知

    公开(公告)号:BRPI0620760A2

    公开(公告)日:2011-11-22

    申请号:BRPI0620760

    申请日:2006-12-18

    Abstract: The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula wherein: R 1 , R 2 , and R 3 are as defined herein and pharmaceutically acceptable acid addition salts thereof. These compounds have high affinity and selectivity for GABA A alpha5 receptor binding sites. The invention also relates to methods for enhancing cognition and treating cognitive disorders like Alzheimer's disease.

    DERIVADOS DE IMIDAZO-BENZODIAZEPINA.

    公开(公告)号:ES2348356T3

    公开(公告)日:2010-12-03

    申请号:ES06806921

    申请日:2006-10-02

    Abstract: Derivados sustituidos de imidazo[1,5a][1,2,4]triazolo[1,5-d][1,4]benzodiazepina de fórmula: **(Ver fórmula)** en la que: R1/R1' son, de manera mutuamente independiente, hidrógeno, hidroxi, alquilo inferior, alquinilo inferior, halógeno, alcoxi inferior, cicloalquilo, o alquilo inferior o alcoxi, sustituidos con halógeno, X es -CH2-, -CH(CH3)-, -CH2O-, -CRR'- o -C(O)-, R2 es -(CH2)n-O-alquilo inferior, halógeno, -NHCH3, N(CH3)C(O)-cicloalquilo, -N(CH3)C(O)-alquilo inferior, N(CH3)S(O2)CH3, -NHC(O)CH2OC(O)CH3, -CF3, cicloalquilo, hidroxi, -CH2OH, ciano, S(O)2CH3, -CH(OH)-alquilo inferior, arilo no sustituido o sustituido con alcoxi nferior, o es un anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, y en el que los anillos pueden 20 encontrarse no sustituidos o encontrarse sustituidos con 1 a 4 sustituyentes seleccionados de entre el grupo que consiste de alquilo inferior, alcoxi inferior, cicloalquilo, =O, CF3, CN, C(O)O-alqilo inferior, bencilo, fenilo, -CH2O-alquilo inferior, CHO o 3-bromo-10-cloro-9H-imidazo[1,525 a][1,2,4]triazolo[1,5-d][1,4]benzodiazepín-6-ilmetil, o es C(O)-O-alquilo inferior, -C(O)NH-(CH2)n-cicloalquilo, C(O)NH-(CH2)n-anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, -C(O)NH-(CH2)nOH, C(O)-anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, no sustituido o sustituido con alquilo inferior, o es -NH-C(O)H o -N(CH3)-C(O)H, -NHC(O)-alquilo inferior, -NH-C(O)-cicloalquilo, -NH-C(O)-Oalquilo inferior, -NH-C(O)-N-dialquilo inferior, -NH-C(O)CH2-O-alquilo inferior o -NH-C(O)-CH2-OH, -NH-(CH2)ncicloalquilo, -NH-(CH2)nS(O)2CH3, -NH-(CH2)n-anillo heterocíclico aromático o no aromático, que contiene entre 1y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, -NH-(CH2)nOH, o X-R2 es alquilo inferior con la excepción de metilo, o es cicloalquilo, no sustituido o sustituido con alquilo inferior o hidroxi, o es un anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, o es -CHRR', R es hidroxi, y R' es cicloalquilo, alquilo inferior, alquilo inferior sustituido con halógeno, fenilo o piridinilo, R3 es hidrógeno, halógeno, C(O)O-alquilo inferior, CH2OH CHO, alquilo inferior o alquilo inferior sustituido con halógeno, n es 0, 1 ó 2, en la que arilo se refiere a un grupo fenilo, bencilo o naftilo, y ; en la que alquilo inferior se refiere a un grupo alquilo de cadena lineal o ramificada que contiene entre 1 y 7 átomos de carbono, y en la que alcoxi inferior se refiere a un grupo alquilo de cadena lineal o ramificada que contiene entre 1 y 7 átomos de carbono que se encuentra unido mediante un grupo de oxígeno, y en la que alquinilo inferior se refiere a un grupo de carbonos de cadena lineal o ramificada que contiene entre 2 y 7 átomos de carbono, en la que por lo menos un enlace es un triple enlace, y las sales de adición de ácido farmacéuticamente aceptables de los mismos.

Patent Agency Ranking